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https://doi.org/10.1016/j.cell.2020.03.047SUMMARYChronic obstructive pulmonary disease (COPD) is a progressive condition of chronic bronchitis, small airway
obstruction, and emphysema that represents a leading cause of death worldwide. While inflammation,
fibrosis, mucus hypersecretion, and metaplastic epithelial lesions are hallmarks of this disease, their origins
and dependent relationships remain unclear. Here we apply single-cell cloning technologies to lung tissue of
patients with andwithout COPD. Unlike control lungs, which were dominated by normal distal airway progen-
itor cells, COPD lungs were inundated by three variant progenitors epigenetically committed to distinct
metaplastic lesions. When transplanted to immunodeficient mice, these variant clones induced pathology
akin to the mucous and squamous metaplasia, neutrophilic inflammation, and fibrosis seen in COPD.
Remarkably, similar variants pre-exist as minor constituents of control and fetal lung and conceivably act
in normal processes of immune surveillance. However, these same variants likely catalyze the pathologic
and progressive features of COPD when expanded to high numbers.INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is an inflamma-
tory condition of the lung marked by chronic bronchitis, small 
airway occlusion, inflammation, fibrosis, and emphysematous 
destruction of alveoli (Barnes et al., 2015; Decramer et al., 
2012; Hogg et al., 2004; McDonough et al., 2011). The global 
impact of COPD is enormous as evidenced by the 250 million pa-
tients with this condition and the 50%, 5-year survival of those 
with Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) stage 3 and 4 disease (FEV1<50%) (Barnes et al., 
2015; Decramer et al., 2012; Hogg et al., 2004; McDonoughet al., 2011; Quaderi and Hurst, 2018; Singh et al., 2019). Risk
factors include chronic exposure to cigarette smoke and envi-
ronmental pollutants; early-life respiratory illnesses such as
asthma, viral pneumonia, and perinatal bronchopulmonary
dysplasia; as well as genetics (Busch et al., 2017; Fletcher and
Peto, 1977; Martinez, 2016; Martinez et al., 2018; McGeachie
et al., 2016). Given that 80% of COPD cases are associated
with long-term chronic smoking, absolute abstinence will limit
risk for this disease. However, the success of smoking cessation
programs on patients with established COPD has been disap-
pointing (Barnes, 2016; Fletcher and Peto, 1977; Gamble et al.,




Figure 1. Epithelial Clone Heterogeneity in COPD
(A) Schematic depicting workflow of generating p63+ epithelial colony pools from resected normal and COPD lung tissue. Individual colonies are captured and
expanded individually to generate clonal cell lines. Scale bar, 500 mm.
(B) Principal component analysis of RNA-seq differential expression genes (DEGs) (false discovery rate [FDR] < 0.05) derived from multiple clones from control
(SPN-12, -14) and COPD (SPN-13, -07) lungs.
(C) RNA-seqexpression heatmapof the clones depicted in the principal-component analysis (PCA) plot is shown highlighting cluster 1 (control) versus clusters 1–4
in COPD (detailed in Table S4).
(legend continued on next page)
et al., 2000; Wen et al., 2010), and most people with moderate
COPD progress to severe disease (FEV1<30) in a 5- to 20-year
interval despite tobacco cessation. The mechanistic basis for
this dogged progression of COPD is unclear, but multiple studies
have shown that lung inflammatory pathways remain activated
years after smoking cessation (Barnes, 2016; Gamble et al.,
2007; Miller et al., 2011; Scanlon et al., 2000; Wen et al., 2010).
The predisposing influences of early-life pulmonary disease,
coupled with the general irreversibility of this condition in previous
smokers, suggest that inertialprocessesmaydriveCOPD.Consis-
tent with this notion, squamous cell metaplasia (SCM) and goblet
cell metaplasia (GCM) typically observed in COPD likewise are
not fully abolished by smoking cessation (Hogg and Timens,
2009; Lapperre et al., 2007; Raju et al., 2016; Zhou-Suckow
et al., 2017). This persistence was surprising, as metaplasia has
been tied to acute effects of cigarette smoke and inflammatory
cytokinesonnormal airwayprogenitors (Arayaetal., 2007;Scham-
berger et al., 2015; Wills-Karp et al., 1998). Removal of these
toxicants was expected to enable distal airway progenitors to
resume their roles in restoring tissue homeostasis in small airways
and terminal bronchioles (Kumar et al., 2011; Ray et al., 2016;
Tanaka et al., 2018; Vaughan et al., 2015; Yang et al., 2018; Zuo
et al., 2015). In this context, we speculated that some irreversible
alterations in distal airway progenitors explain their inability to
restore airwayand lunghomeostasis following smoking cessation.
In the present study, we leveraged robust technologies that
enable the cloning of distal airway epithelial cells (Kumar et al.,
2011; Zuo et al., 2015) to perform a comparative analysis of clo-
nogenic cells in patients with and without COPD. The data re-
vealed that the COPD distal airways are populated by a highly
stereotyped triad of clonogenic cells in addition to the normal
clonogenic cell type that predominates control lungs. We show
here these variants are stably committed to metaplastic fates
and autonomously drive proinflammatory and pro-fibrotic pro-
grams akin to those implicated in COPD pathology. Lastly, we
show that a similar triad of clonogenic cells in COPD also exists
in control adult and 13-, 14-, and 17-week fetal lung, albeit at low
ratios to the predominant distal airway clone type seen in normal
lung. Thus, the variant clones predate any disease state and yet
have features that could contribute to the emergence, pathol-
ogy, or progression of COPD as a function of their numbers.
RESULTS
Heterogeneity of Clonogenic Cells in COPD
Libraries of clonogenic epithelial cells from resected lung tissue
of 19 COPD and 11 control patients (Table S1) were generated
by selective colony growth on lawns of irradiated, 3T3-J2 feeder
cells (Kumar et al., 2011; Zuo et al., 2015; detailed in STAR
Methods). In brief, approximately 0.85 ± 0.04% of all enzymati-
cally digested lung cells yielded colonies from COPD patients
and 0.15 ± 0.02% from controls (Table S2). These libraries
have a complexity of 2,000 to 20,000 independent colonies per(D) Top: individual colonies from cloned representatives of clusters 1–4 stained wit
rhodamine red-stained colonies arising on lawns of irradiated 3T3-J2 fibroblast
histogram of clonogenicity based on percentage of plated cells that formed coloni
Data represented as mean ± SEM; See also Tables S1 and S4.cubic centimeter of lung tissue and consist exclusively of cells
that co-express E-cadherin and p63 (Ecad+/p63+). Single cells
from these patient-specific libraries have a clonogenicity of
greater than 50% as judged by single cell sorting to 384-well
plates and give rise to discrete lines of highly immature epithelial
cells characterized by a long-term (> 1 year) proliferative poten-
tial. Randomly sampled clones from libraries of control patients
(SPN-12, -14) displayed whole genome expression profiles
consistent with previously characterized clonogenic cells of
distal airways (Kumar et al., 2011; Zuo et al., 2015) (Figures 1B
and 1C). In contrast, sampled clones from libraries derived
from COPD patients (SPN-7, -13) yielded a more complex spec-
trum of gene expression profiles. In addition to the normal distal
airway clones (hereafter ‘‘cluster 1’’), the majority of sampled
clones showed whole genome expression profiles that diverged
from cluster 1 and readily segregated into three additional
distinct clusters (clusters 2, 3, and 4) (Figures 1B and 1C).
Despite this clonal heterogeneity in COPD, all clones from clus-
ters 1–4 shared the expression of established markers of distal
airway progenitors (p63, KRT5), displayed a clonogenicity of 60
± 1.4%, and showed a long-term proliferative potential of at least
25 passages (> 8 months) while maintaining a clonogenicity of
59.9 ± 1.6% (Figure 1D). Herein we leverage the regenerative
properties of these patient-specific libraries of clonogenic cells
and the single cell-derived clones from them to assess the prop-
erties of epithelial progenitors in COPD and control cases.
Metaplastic Fate Commitment of COPD Clones
In vitro differentiation of cluster 1 clones from both COPD and
control libraries yielded normal epithelia (NM) marked by p63+
basal cells and suprabasal, differentiated cells expressing
SCGB1A1, SFTPB, and AQP4, similar to human epithelia of small
airways and terminal bronchioles (Figures 2A, S1A, and S1B). In
contrast, clones of cluster 2 differentiated to a GCM marked by
p63+ basal cells and differentiated goblet cells co-expressing
SCGB1A1, MUC5AC, and MUC5B, whereas clones from clus-
ters 3 and 4 gave rise to SCM marked by immature p63 cells
and differentiated keratin 10 (Krt10)- and involucrin (IVL)-ex-
pressing cells (Figures 2A and S1A).
We further tested the fates of cluster-specific clones in vivo by
transplanting discrete clones into highly immunodeficient NSG
(NODscidIL2ranull) (Shultz et al., 1995) mice. Briefly, 1million cells
of a designated clone were mixed with 50% Matrigel and in-
jected subcutaneously, and the resulting xenograft nodule was
examined four weeks later (Figure 2B). Significantly, normal con-
trol clones, as well as those from cluster 1 of COPD patients,
assembled into a polarized epithelium in vivo comprised of cells
positive for p63, KRT5, SCGB1A1, AQP4, AQP5, SFTPB, and
SFTPC (Figures 2C and 2D) like that of normal human terminal
bronchioles (Figure S1B) or that produced by in vitro differentia-
tion of cluster 1 clones (Figures 2A and S1A). Also mirroring the
in vitro air-liquid interface (ALI) cultures, the xenografts of cluster
2 clones from COPD libraries formed an epithelium dominatedh antibody to p63 showing uniform nuclear staining. Scale bar, 100 mm. Bottom: 
s from 500 cells from each of cloned representatives of clusters 1–4. Right: 
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by large goblet cells (Figures 2C, 2D, and S1D) expressing
MUC5AC and MUC5B (Fahy and Dickey, 2010; Kesimer et al.,
2017; Okuda et al., 2019), and both cluster 3 and 4 clone
xenografts yielded SCM-expressing IVL and Krt10 (Figures 2C,
2D, S1E, and S1F). Despite their commitment to histologically
similar SCM, cluster 3 and 4 clones exhibit distinct gene
expression profiles (Figures 1B and 1C). cluster 4 clones in
particular constitutively express a broad array of genes related
to inflammation and are denoted herein as ‘inflammatory SCM’
or ‘iSCM’ versus ‘SCM’ for cluster 3 clones. Importantly,
the respective differentiation fates of these clone types in xeno-
grafts proved to be remarkably stable to 250 days of continuous
propagation in vitro, suggesting that these metaplasia are the
consequences of highly stable, cell-autonomous fate programs
(Figure 2E). Lastly, whole exome DNA sequencing of cluster 2,
3, and 4 clones derived from these COPD patients showed
an absence of copy number variation events greater than 10Kb
(Figure 2F). Moreover, the 127–157 single nucleotide variation
(synonymous, nonsynonymous, indels) events in these clones
were consistent in number with other somatic cells (Lee-Six
et al., 2018) and did not impact known tumor suppressors or
oncogenes such as p16 or p53 (Figures 2G and S1G; Table
S5), arguing against the possibility these clones are related to
neoplastic lesions.
Metaplastic Lesions Dominate End-Stage COPD Lung
Given the observation that the cluster 1–4 clones expressed p63
and yet differentiated to cluster-specific metaplasia in vitro and
in vivo, we asked if metaplasia in the distal airways of COPD
lung exhibited a similar association with p63+ basal cells.
To address this question, we morphometrically quantified the
distribution of normal distal airway epithelia and metaplasia in
histological sections of distal lung from five additional donors
lacking lung or systemic disease as well as from an additional
10 lungs of Stage 4 COPD transplant recipients (Table S3).
Whereas metaplastic lesions in the normal lungs were rare, the
end-stage COPD distal airways were replete with GCM
(MUC5AC+) and SCM (IVL+) that, like normal distal airway
epithelia, were subtended by basally positioned p63+ cells (Fig-
ure 3A). In quantitative terms, GCMoccupied amean of 32.7%of
the distal airway epithelia (defined as that subtended by p63+
basal cells) of COPD lung versus 5.7% of the normal lungs,
SCM occupied 26.8% of the COPD airways epithelia comparedFigure 2. Commitment of Variant Clones to Metaplastic Fates
(A) From left, schematic of clonal expansion and differentiation in air-liquid interf
Cluster 1 clones differentiated to an epithelium characterized by expression of S
clones differentiated into an epithelium characterized by SCGB1A1+, MUC5AC
squamous epithelia that expressed involucrin (IVL) but not SCGB1A1, AQP4, or
(B) Schematic of subcutaneous transplants of immature cells from clones or lib
processed for histology and immunostaining and showed polarized epithelia t
bar, 100 mm.
(C and D) In vivo differentiation following subcutaneous transplantation of clone
(MUC5AC+; GCM), and clusters 3 and 4 (IVL+; SCM). Scale bar, 100 mm.
(E) Xenografts of cluster 1–4 clones previously grown in vitro to P5 and P25 show
Scale bar, 100um.
(F) Copy number and single nucleotide variation analysis derived from whole exom
patient blood. Copy number variation (CNV) events of larger than 10–20Kb were
nucleotide variants (SNVs) (synonymous, non-synonymous, indels) in each cloneto less than 1% in normal lungs, and iSCM constituted approxi-
mately 21.6% of COPD airways and was not detected in normal
lungs (Figure 3B). We also examined the distribution of marker
genes associated with the p63+ basal cells of normal (AQP5+),
iSCM (CXCL8+), and SCM or GCM (TRPC6+) airway epithelia
in the same normal and Stage 4 COPD lungs (Figure 3C). Consis-
tent with our morphometric analyses of lungmetaplasia in COPD
and control lung, CXCL8+ basal cells of iSCM comprised 19.3%
of all p63+ distal airway basal cells of COPD lung, while these
were not observed in normal lungs. Fully 52% of the basal cells
in COPD lung expressed TRPC6, a marker of both GCM and
SCM, while fewer than 2% of basal cells showed TRPC6 expres-
sion in the normal lungs (Figures 3D and S2). The close associa-
tion of p63+ cells with the major forms of metaplasia in COPD is
consistent with our finding that COPD lung possesses an
array of p63+ clonogenic cells with absolute commitments to
normal airway epithelia, GCM, or SCM. These findings are also
in agreement with earlier studies that showed metaplasia in
COPD and idiopathic pulmonary fibrosis (IPF) were subtended
by p63+ cells (Araya et al., 2007; Chilosi et al., 2002; Plantier
et al., 2011; Seibold et al., 2013; Smirnova et al., 2016).Clonal Architecture of COPD and Control Libraries
We next asked if the widespread distribution of metaplastic le-
sions in the distal airways of end-stage COPD lung was reflected
in the properties of the clonogenic cell libraries generated from
our 19 COPD and 11 non-COPD cases. Single-cell RNA
sequencing (scRNA-seq) (Satija et al., 2015) analyses of three
COPD and three control libraries revealed four major clusters
with gene expression profiles similar to those identified by single
colony sampling as clusters 1–4 (Figures 3E and S3). In partic-
ular, the three COPD lungs showed major contributions to the
clonal architecture of these libraries by clones committed to
GCM, SCM, and iSCM represented by clusters 2, 3, and 4,
respectively. The coherence between markers identified by
scRNA-seq and by RNA-seq of representative clones of each
cluster was high, suggesting that our sampling approach likely
captured all major clone variants in the COPD patients (Figures
3E and S3A). This analysis also indicated that while control li-
braries were dominated by cluster 1 clones committed to distal
airway epithelia, these libraries also harbored small percentages
(6%–12%) of metaplastic variants (Figures 3E and S3B).ace (ALI) cultures assessed by immunofluorescence on histological sections.
CGB1A1, SFTPB, a-TUB, and AQP4 and the absence of MUC5AC. Cluster 2
+, and AQP4- goblet cells. cluster 3 and cluster 4 clones differentiated into
SFTPB. Scale bar, 100 mm.
rary of clones into immunodeficient mice. Nodules formed at 4 weeks were
hat reacted with antibodies to the human-specific marker STEM121. Scale
d representatives of cluster 1 (SCGB1A1+, SFTPB+, and AQP4+), cluster 2
ing stability of fate differentiation and expression of cluster-specific markers.
e sequencing of representative clones of clusters 1–4 from SPN-13 relative to
not detected in any of the clones. Venn diagram of all detected exonic single-
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To develop a more simplified means of assessing the hetero-
geneity of clone libraries fromCOPD and control patients, we ex-
ploited the consensus markers identified by scRNA-seq and
RNAs-eq of representative clones for quantitative flow cytometry
(FACS) analysis. Antibodies to AQP5 were specific to cluster 1
cells, CXCL8 for cluster 4 cells, and TRPC6 antibodies for both
clusters 2 and 3 (Figure 4A). This limited set of markers was
used to quantify the relative distribution of clone variants across
our 19 COPD and 11 control patients (Figures 4A and 4B; Table
S1). Consistent with our analyses of scRNA-seq profiles, the
quantification of clone types by flow cytometric analyses of
markers showed that variants (TRPC6+ for clusters 2 and 3;
CXCL8+ for cluster 4) comprised 77.7 ± 5% of all cells in the
19 COPD clone libraries, while in control specimens, 12.2 ±
6% of the p63+ clonogenic cells in the 11 control libraries fell
within clusters 2–4 based on FACS analyses of markers
TRPC6 and CXCL8 (p < 2.2e-16; Figures 4B and S4A; Table S2).
Xenografts of COPD Clone Libraries Drive Neutrophilic
Inflammation
To assess the pathogenic potential of the COPD epithelial cells,
we performed subcutaneous transplants of composite clone li-
braries of each of the 19 COPD patients and 11 control patients
into immunodeficient mice. Over four weeks, clone libraries from
control patients yielded epithelial cysts with appropriate basal-
apical polarity around largely vacant spaces (Figures 4C and
S4B; Table S2). In contrast, clone libraries generated from
COPD patients produced cysts occupied by dense arrays of
epithelial and non-epithelial cells (Figures 4D and S4C; Table
S2). The majority of non-epithelial luminal cells were hematopoi-
etic in origin as evidenced by anti-murine CD45 staining, and the
majority of those were positive for antibodies to Ly6G, a marker
of neutrophils (Figure 4D). Similar patterns of leukocyte transepi-
thelial migration (TEM) (Brazil and Parkos, 2016) are present in
COPD lung (Barnes et al., 2015; Butler et al., 2018; Quint and
Wedzicha, 2007). Quantification of the extent of neutrophil infil-
tration at the level of individual epithelial cysts revealed that
36.4 ± 14% of these cysts scored ‘‘severe’’ (closest neutrophil
packing) in the COPD clone library xenografts in contrast to
only 0.3 ± 0.9% of the cysts in control library xenografts
(p = 1.2e-09, Student’s t test; Figures 4E and S4D).
Given the robust inflammatory response triggered by xeno-
grafts of COPD clone libraries, we asked if this inflammatoryFigure 3. p63+ Cells in COPD Metaplasia and Clone Libraries
(A) Top: p63 immunohistochemistry of distal lung of GOLD Stage 4 COPD showing
Scale bar, 200 mm. Bottom: immunofluorescence micrographs of expanded reg
MUC5AC (red). Scale bar, 100 mm.
(B) Box-whisker plots for the linear occupancy of metaplastic lesions (GCM of p =
distal airways ten Stage 4 COPD lungs compared with five normal lungs witho
quartile, and minimum.
(C) Top: p63 immunohistochemistry micrographs of regions of COPD distal airwa
bar, 200 mm. Bottom: immunofluorescence micrographs of expanded regions o
CXCL8+). Scale bar, 100 mm.
(D) Box-whisker plots of distribution of CXCL8+ (p = 2.5e-06, Student’s t test) and
distal lung compared with five normal lungs. Box-whisker plot indicates maximu
(E) Single and aggregate t-distributed stochastic neighbor embedding (tSNE) profile
charts indicate the fractional contributions of clones of clusters 1–4 to patient-spe
Figures S2 and S3; Tables S3, S6, and S7.activity was a function of one or more of the constituent clone
types. Using pathway enrichment analysis algorithms for the
gene expression profiles of the four clone types, we found that
cluster 4 clones, but not those of clusters 1, 2, or 3, displayed
multiple inflammatory pathways including Antigen Presentation,
Interferon Signaling,Graft-versus-Host responses, andDendritic
Cell Maturation (Figures 5A and S5A). We tested media condi-
tioned by clones of clusters 1–4 for their ability to trigger phase
I and II activation of human airway microvasculature endothelial
cells, an essential step in leukocyte recruitment (Filippi, 2016).
Endothelial cell activation was assessed by the expression of
Vcam1 (CD106), a vascular adhesion protein that binds VLA-1
(alpha4beta1 integrin) on monocytes and lymphocytes, and it
was found that cluster 1 clones from COPD patients showed
no induction, whereas IL-13 challenge yielded a 30-fold induc-
tion of Vcam1 (Figure S5B). In this same assay, media condi-
tioned by cluster 2 (GCM) or cluster 3 (SCM) clones, respectively,
yielded 4- and 10-fold inductions of VCAM1, and media from
cluster 4 (iSCM) clones induced Vcam1 by 60-fold (Figure S5B).
These data provide functional support for the notion that individ-
ual clone variants can promote, at least in vitro, an early step in
inflammatory responses.
A more detailed expression heatmap of the variant clones re-
vealed that cluster 4 clones in particular displayed a constitutive
expression of a broad array of chemokines, interleukins, and
interferon genes compared to clones fromcluster 1, 2, and 3 (Fig-
ures 5B and S5C). Among the large array of cluster 4-specific
chemokines were key determinants of neutrophil responses
including CXCL1, CXCL5, and CXCL8 (Barnes, 2016; Brazil and
Parkos, 2016; Ponce-Gallegos et al., 2017; Traves et al., 2002),
the lymphocyte and dendritic cell chemoattractant CCL20 (De-
medtset al., 2007), andothers suchasCXCL10and11 implicated
in Th1 responses (Tokunaga et al., 2018). In addition, cluster 4
clones expressed a broad array of interleukin genes, including
IL1a, IL1b, IL6, IL17C, and IL33, known to interact with multiple
cellular mediators of the innate and adaptive immune response
(Barnes, 2016; Byers et al., 2013; Holtzman et al., 2014). Lastly,
this analysis highlighted cluster 4 clones as a robust source of
Type I and Type II interferon pathway genes typically induced
by viral infection (Schneider et al., 2014). In fact, cluster 4 clones
showed a constitutively high expression of genes implicated in
the entire interferon-g pathway, including those involved in
recognition of pathogen-associated molecular patternscontiguous regions of SCM and GCM subtended by p63+ basal cells (brown).
ions of SCM and GCM stained with antibodies to p63 (green), IVL (red) and
4.1e-06, SCM of p = 1.2e-07, and iSCM of p = 4.9e-07, Student’s t test) across
ut disease. Box-whisker plot indicates maximum, third quartile, median, first
ys showing, from left, examples of terminal bronchiole, GCM, and SCM. Scale
f terminal bronchiole (p63+, Aqp5+), GCM (p63+, TRPC6+), and iSCM (p63+,
TRPC6+ basal cells (p = 1.2e-08, Student’s t test) in 10 cases of Stage 4 COPD
m, third quartile, median, first quartile, and minimum.
s of single cell RNA-seq data of threeCOPDand three control clone libraries. Pie
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(PAMPs), such as TLR2, TLR3, andMYD88; transcription factors
driving the interferon-response genes (IRF1, IRF6, IRF7, and
IRF9); as well as genes in the JAK-STAT pathway that cooperate
in driving the interferon response such as STAT1, STAT2, and
JAK1 (Figures 5BandS5C). Togetherwith the patterns of chemo-
kine and interleukin gene expression, these data suggest the
potential of cluster 4 clones to promote an inflammatory
response involving diverse cells of the immune system.
To directly test the prediction that cluster 4 clones were
primarily responsible for host neutrophil responses in whole
COPD library transplants (cf. Figure 4D), we performed xeno-
grafts of the individual clone types in immunodeficient mice.
Significantly, nodules formed by xenografts of cluster 4 clones
showed robust leukocyte infiltration (Figure 5C). Consistent
with their proinflammatory properties in xenografts, the epithelial
cysts formed by cluster 4 clones were unique among the four
clone types by showing high protein expression of multiple in-
flammatorymediators suchas IL33,CXCL8, and IL1b (Figure 5D).
Lastly, the leukocyte infiltration response to cluster 4 clones
proved stable for eight months of continuous propagation
in vitro (Figures 5E and 5F), suggesting that their proinflamma-
tory activity is epigenetically maintained. Together, these data
support the conclusion that cluster 4 clones play a major and
likely autonomous role in promoting the observed host leukocyte
responses observed in the COPD clone library transplants.
Clonogenic Variants Drive Fibrosis
Fibrosis of small airways and respiratory vasculature is an estab-
lished feature of COPD (Araya andNishimura, 2010; Aschner and
Downey, 2016; Barnes, 2016; Hogg and Timens, 2009) and has
been associatedwith TGFb-induced activation ofmyofibroblasts
(Black et al., 2019;Murphy-Ullrich and Suto, 2018). In this regard,
we observed that many of the epithelial cysts in xenographs of
clone libraries from all 19 COPD patients were surrounded by
dense layers of fibroblast-like cells (Figure 4D). Antibodies to
alpha smooth muscle actin (a-SMA), a key marker of activated
myofibroblasts, labeled these submucosal assemblies along
the majority (77.1 ± 7.2%) of the perimeter of the epithelial cysts
in COPD xenografts, whereas only relatively few of these cysts in
control xenografts showed these myofibroblast arrays (12.9 ±
8.1%; p = 7.044e-15, Student’s t test; Figures 6A–6C, S6A, and
S6B). Similar accumulations of submucosal myofibroblasts
were observed in xenographs of single cluster 3 or cluster 4
clonesbut not in xenograftsof clonesof clusters1or2 (Figure6D).
These data link the two SCMs produced by clusters 3 and 4
clones, but not GCMor normal airway epithelia, to the accumula-
tion of myofibroblasts. Consistently, gene expression profiling of
xenografts derived from clones of the respective clusters re-Figure 4. Library Composition and Proinflammatory Response in Xeno
(A) FACS profiles of COPD and control clone libraries usingmarkers established fr
TRPC6 (clusters 2 and 3), and anti-CXCL8 (cluster 4).
(B) Histogram compiling FACS quantification data on the relative clone composi
(C) Histological sections of four-week xenograft of clone libraries from control (S
(D) Histological sections of four-week xenograft of clone libraries from COPD cas
Ly6G+ leukocytes (insets).
(E) Histogram depicting the quantification of leukocyte infiltration in xenografts of c
cells in cysts (right). Scale bar, 100 mm. See also Figure S4.vealed differential expression of multiple, pro-fibrotic genes in
xenografts of clones of cluster 3 and 4 that were not evident in
xenografts of cluster 1 (Figure 6E). Among this large set of consti-
tutively expressed genes implicated in the regulation of fibrosis
were TGFb3, GDF15, and TGFbR2; downstream genes including
collagen isotypes (e.g., COL1A1); matrix metallopeptidases
(MMP7, MMP13); and BACH1 (Dhakshinamoorthy et al., 2005),
a transcriptional repressor of the Nrf2-activated antioxidant
pathway known to suppress fibrosis in multiple tissues
(Figure 6F). Finally, like the proinflammatory effect of cluster 4,
the pro-fibrotic effects of clones of clusters 3 and 4 were stable
to long-term propagation in vitro (Figure S6C).
Pre-existence of Variant Clone Types in Normal and
Fetal Lungs
If the variant clones that dominate COPD lung indeed contribute
to the disease process, their origin becomes a central question.
These variant clones, all of which express p63, conceivably arise
from an epigenetic ‘‘reprogramming’’ of normal, p63+ distal
airway clones. Alternatively, these variant cells might already
exist as distinct lineages in the normal distal airway epithelia,
albeit at low ratios to the distal airway progenitor. In support of
the pre-existence model, both scRNA-seq and FACS profiles
of control lungs indicated an aggregate representation of variant
clones of approximately 10% (Figures 3E and 4B), and direct
cloning from control libraries showed that these variants
possessed corresponding metaplastic fate commitment and
pathological activity in xenografts (Figure S7A). Consistently,
expression data of cluster 1–4 clones from control case SPN-
14 showed significant overlap with those of COPD cases (Fig-
ures S3A and S7B; Table S8). However, we could not rule out
the possibility that at least some of the control cases had
‘‘sub-clinical’’ disease reflected by these variant clones. To
more definitively address this question, we examined the clonal
architecture of libraries generated from 13- and 17-week fetal
lungs (Figures 7A and S7C). Remarkably, scRNA-seq profiles
of the clone libraries of these pseudoglandular fetal lungs
(Schittny, 2017) revealed minor populations of clones similar to
those of cluster 2, 3, and 4 variants (in aggregate, 17%–34%)
among a majority of normal cluster 1 clones (Figure 7B, S7D,
and S7E). The similarity of these four fetal clone types with those
of clusters 1–4 fromCOPD cases was confirmed by their respec-
tive differentiation fate in vitro and upon xenografting, at the level
of gene expression, and finally by their corresponding potential
to drive mucus hypersecretion (GCM), fibrosis (SCM and
iSCM), and neutrophilic inflammation (iSCM) (Figures 7C and
7D). The pre-existence of these variant clone types in both
normal adult lung and in developing fetal lung favors somegrafts
om library scRNA-seq and clonal RNA-seq including anti-AQP5 (cluster 1), anti-
tion of each patient library.
PN-21) showing epithelial cysts devoid of luminal cells.
e (SPN-04) showing epithelial cysts marked by abundant infiltration of CD45+/
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unknown, normal function of these variants in the lung as well as
the notion that the evolution of COPD involves a pathological and
irreversible expansion of these variant populations that, in turn,
drives the disease process.
DISCUSSION
The abnormal clonogenic cell types in COPD lungs offer new
insights into the natural history of COPD. The fates and biological
properties of the three major clone types (GCM, SCM, and
iSCM) in the COPD lung appear to be autonomously maintained
and, in aggregate, they dominate the epithelia of moderate and
end-stage COPD. There are two implications of this work. One
is that these clonogenic variants are stem cells respectively
committed to metaplastic lesions that, in turn, promote the
fibrotic and inflammatory processes observed in COPD. The
second is that these variant cells or the factors they secrete
may represent important therapeutic targets in this disease.
The clonal analysis described here was instrumental in
defining the heterogeneity of clonogenic epithelial cells in
COPD. Unlike the normal cluster 1 clones committed to distal
bronchiolar fates, the three variant types exhibited distinct path-
ologic phenotypes, with cluster 2 clones producing a GCM
marked by the excess mucin secretion implicated in airway oc-
clusion (Fahy and Dickey, 2010; Kesimer et al., 2017; Wedzicha,
2017), while SCM (cluster 3) clones induced an activation of
airway endothelial cells in vitro and, in immunodeficient mice, a
host myofibroblast response linked to fibrosis. cluster 4 clones
not only activated endothelial cells in vitro but triggered both
submucosal myofibroblast recruitment and leukocyte infiltration
upon xenografting to immunodeficient mice. Given that the un-
parsed clone libraries from all 19 COPD patients induced leuko-
cyte infiltration whereas only 1 of the 11 controls did so, as well
as the major role of inflammation in this disease (Barnes, 2016;
Brazil and Parkos, 2016; Butler et al., 2018), we predict that clus-
ter 4 clones will figure prominently in the evolution of COPD.
It shouldbeemphasized that the inflammatory genesexpressed
in proliferating clones isolated from COPD lung are constitutively
activated for months even in a sterile, in vitro environment (Fig-
ure 5). The inflammatory pathways manifest in these cells are
linked to the activation of a broad array of the innate and adaptive
immune cell populations associatedwithCOPD, including neutro-
phils, monocyte-derivedmacrophages and dendritic cells, as well
as a host of T-helper subsets, natural killer cells, andother lineages
such as innate lymphoid cells. Many of these immune cell types
impact the development of fibrosis (Kasembeli et al., 2018; Lee
and Kalluri, 2010). Notably, despite the broad range of the inflam-Figure 5. Cluster 4 COPD Clones Are Constitutively Hyperinflammator
(A) Histogram depicting most significant (p < 1.0e-8) pathways determined by Inge
of patient-matched clones representative of clusters 1–4.
(B) Differential expression heatmaps of chemokine, interleukin, and interferon g
sentative of clusters 1–4 (SPN-13).
(C) Hematoxylin and eosin stain (H&E) on sections through four-week xenografts o
accompanied by abundant intraluminal leukocytes. Scale bar, 100 mm.
(D) Immunofluorescence micrographs of cluster 4 xenografts revealing high expre
Scale bar, 50 mm.
(E) CD45 immunohistochemistry of xenografts derived from cluster 4 clone grow
(F) Histogram of CXCL8, CCL20, and CXCL10 gene expression in clonal represematory pathways expressed in cluster 4 clones, only neutrophil re-
sponses were apparent in xenografts of these cells. At least some
of this restrictedhost responsecanbeattributed to strain of immu-
nodeficient mice (NOD/scid/IL2rgnull) used in these studies, which
lacksmatureBandTcells, natural killer cells, and showsdefects in
monocyte-derived macrophages and dendritic cells (Ito et al.,
2012; Shultz et al., 2005; Shultz et al., 1995). Therefore, we were
unable to assess whether other hematopoietic lineages associ-
ated with COPD (Barnes, 2016; Suzuki et al., 2017) might be
impacted aswell by the variant clones. Xenografts of these clones
in immunodeficient strains having a greater complement of he-
matopoietic lineages may provide a more complete assessment
of interactions between these clones and the immune system, as
would syngeneic studies of homologous variant clones in geneti-
cally tractable model organisms.
This study raises important questions on the origin of the
variant clones detected in COPD, how they become hegemonic,
and what they mean to the etiology and progression of the dis-
ease. Taking just the cluster 4 clone (iSCM) that promotes host
neutrophilic and fibrotic responses as an example, quantitative
FACS profiling showed that it represents 13 ± 8% of all clono-
genic cells across 19 COPD lungs but only 1.4 ± 1.6% of those
in control lungs (Figure 7E). These numbers raise the possibility
that the COPD phenotype becomes apparent at some percent-
age threshold of these clones. We tested this hypothesis in
a tangential manner by asking what ratios of cluster 4 to cluster
1 clones in co-xenografts would elicit a host neutrophil response
(Figure 7F). The resulting xenografts induced a minimal inflam-
matory response when cluster 4 clones comprised less than
5% of the total clones, whereas ratios between 10% and 20%
of cluster 4 clones triggered a robust neutrophil response
(Figure 7G). These findings support the notion that a threshold
phenomenon, tied to the relative ratios of these variant cells,
could be relevant to both the onset of clinical symptoms and
the vectored progression of COPD. We anticipate that additional
modeling of these variant clones singly or in combination will
contribute to understanding their roles in COPD.
Given that similar variant stem cells preexist in control adult
lungs as well as in lungs at multiple stages of fetal development,
it is likely that these variants play some role in the normal lung,
perhaps as sentinels for pathogen incursions. Understanding
the responses of these variants in normal lung may provide in-
sights into their intrinsic functions and how these cells might
be suborned to disease. In this regard, key questions remain
for how these minor variants become major variants in COPD.
How do early-life pulmonary events or chronic smoking set in
motion their numerical expansion, do genetic variations impacty
nuity Pathway Analysis of RNA-seq differentially expressed genes (FDR < 0.05)
enes among RNA-seq DEGs (FDR < 0.05) of patient-matched clones repre-
f patient-matched clones of clusters 1–4 showing that only cluster 4 clones are
ssion in epithelia of inflammatory mediators including IL33, CXCL8, and IL1B.
n in vitro to P5 and to P25. Scale bar, 200 mm.
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these expansion dynamics, does the disease process itself
further alter these variants during the expansion process, and
can this expansion be therapeutically preempted or reversed?
The overall findings here set the stage for more detailed
studies of correlations between the abundance of such clones
and COPD stage as well as their correlation with the known
regional, intrapulmonary variations in COPD pathology (Nambu
et al., 2016).We should note here thatmultiple studies have high-
lighted the possibility that alterations in epithelial cells in IPF,
chronic rhinosinusitis, and COPD may contribute to the pathol-
ogy of these conditions (Byers et al., 2013; Habiel et al., 2018; Or-
dovas-Montanes et al., 2018; Vieira Braga et al., 2019; Xu et al.,
2016). While those studies did not examine clonogenic cells per
se, their findings support the speculation that many if not all
chronic lung conditions involve pathogenic clone variants of
the sort described here.
If indeed these clones contribute to COPD, multiple
opportunities become available to limit their impact on disease
progression. These include neutralizing one or more of the
pathogenically relevant chemokines or cytokines secreted by in-
dividual variants, targeting particular variants with cell surface-
directed antibodies, or through the discovery of small molecules
that selectively affect one or more of these clone types. This
latter strategy could be predicated on the observation that
COPD patients retain normal clones that would potentially
compensate for the loss of their pathogenic counterparts.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Subjects
The lung tissues used in this study were from resected lobes, lung transplants, or fetal demise cases that were obtained under
informed consent as de-identified material under approved institutional review board protocols at the University of Connecticut
Health Sciences (IRB# 08-310-1), the University of Iowa Carver College of Medicine (IRB# 199507432), the University of Texas Health
Sciences Center, Houston (HSC-MS-08-0354/HSC-MS-15-1049), and the Brigham and Women’s Hospital, Boston, MA
(2009P002281), respectively. Relevant patient data is listed in Table S2.
Primary Cell Culture
The primary cells used in this study were derived from human lung tissues. All cells were cultured in StemECHOTMPU culture me-
dium (Nüwa Medical Systems, Houston, USA). The cells were tested as mycoplasma-free. Single Nucleotide Polymorphisms (SNPs)
detected in RNA-seq data were used as genotyping marker to ensure the authentication of each cell line.
Animals
All animal experiments have been approved by the Animal Care Committee at the University of Houston (IACUC 16-002). Human lung
cell variants were subcutaneously transplanted to NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice. Animal studies were conducted
under maximum containment in an animal biosafety level 2 facility. NSG mice were immune-compromised, drug or test naive, and
housed in a sterile condition. Both male and female mice (6-8 weeks old) were utilized in these studies. At 3 weeks post-transplant,
mice were humanely euthanized according to IACUC-approved criteria.
Cell Lines
Human Lung Microvascular Endothelial Cells (HMVEC-L, human [Homo sapiens]) were obtained from Lonza (https://bioscience.
lonza.com/lonza_bs/CH/en/). HMVEC-L cells were cultured in EGMTM 2 MV medium purchased from Lonza (Cat# CC-3202).
All cell lines were incubated at 37C with 7.5% CO2.
METHOD DETAILS
In vitro culture of clonogenic cells from 19 COPD and 11 control lungs
Minced lung tissuewas digested in 2mg/mL collagenase type IV (GIBCO, USA) at 37C for 30-60min with agitation. Dissociated cells
were passed through a 70 mmNylon mesh (Falcon, USA) to remove masses and then were washed four times in cold F12 media, and
seeded onto a feeder layer of lethally irradiated 3T3-J2 cells as described (Kumar et al., 2011; Zuo et al., 2015) and grown in StemE-
CHOTMPU culture medium (Nüwa Medical Systems, Houston, USA). In each case, approximately 2 to 4 3 106 cells were obtained
per cubic centimeter of lung tissue after erythrocyte lysis of which 200-400 thousand expressed E-cadherin. 1 million of these disso-
ciated lung cells were seeded onto lawns of irradiated 3T3-J2 feeder cells. In the control cases, 1,500 to 2,300 colonies were
observed at P0 after seeding, indicating that 0.15% to 0.23% of all cells were clonogenic. For COPD cases, we obtained 4,500 to
8,000 colonies at P0, indicating that 0.45% to 0.8% of all lung cells were clonogenic. The culture media was changed every two
days. Colonies were digested by 0.25% trypsin-EDTA solution (GIBCO, USA) for 5-8 min and passaged every 7 to 10 days. Colonies
were trypsinized by TrypLE Express solution (GIBCO, USA) for 8-15 min at 37C and cell suspensions were passed through 30 mm
filters (Miltenyi Biotec, Germany). Approximately 20,000 epithelial cells were seeded to each well of 6-well plate. Cloning cylinder
(Pyrex, USA) and high vacuum grease (Dow Corning, USA) were used to select single colonies for pedigrees. Gene expression
analyses were performed on cells derived from passage 4-10 (P4-P10) cultures.
Histology validation set of five control and 10 Stage-4 COPD lungs
To validate the localization of clone-specific metaplasia in situ, we performed histopathology and immunolocalization studies on
serial sections from five control lungs from patients without lung or systemic disease (Okuda et al., 2019) and from 10 patients
with Stage 4 COPD. These histological sections were obtained under IRB approval from the University of North Carolina
(03-1396), the University of Iowa Carver College of Medicine (199507432), and the University of Texas Health Sciences Center
at Houston (HSC-MS-08-0354/HSC-MS-15-1049). Data relevant to the patients of this validation set is presented on Table S3.
Student’s t test was used to determine the statistical difference between groups. p < 0.05 was considered statistically
significant.
Histology and immunostaining
Histology, hematoxylin and eosin (H&E) staining, immunohistochemistry, and immunofluorescence were performed using standard
techniques. For immunofluorescence and immunohistochemistry, 4% paraformaldehyde-fixed, paraffin embedded tissue slides
were subjected to antigen retrieval in citrate buffer (pH 6.0, Sigma-Aldrich, USA) at 120C for 20 min, and a blocking procedure
was performed with 5% bovine serum albumin (BSA, Sigma-Aldrich, USA) and 0.05% Triton X-100 (Sigma-Aldrich, USA) in
DPBS(-) (GIBCO, USA) at room temperature for 1 h. The sources of primary antibodies used in this study include: Rabbit monoclonal
cytokeratin 5 antibody (RM-2106-S; Thermo Fisher, USA); mouse monoclonal human cytokeratin 5 antibody (NCL-L-CK5; Leica 
Biosystems, Germany); mouse monoclonal CC10 antibody (sc-365992; Santa Cruz Biotechnology, USA); rabbit polyclonal AQP4 
antibody (HPA014784; Sigma-Aldrich, USA); rabbit polyclonal SFTPB antibody (HPA034820; Sigma-Aldrich, USA); mouse mono-
clonal acetylated tubulin T7451 (Sigma-Aldrich, USA); rat monoclonal mouse CD45 antibody 14-0451-85 (Thermo Fisher, USA); 
mouse monoclonal human CD45 MAB1430-SP (R&D systems, USA); rat monoclonal mouse Ly6G MAB1037 (R&D systems, 
USA); mouse monoclonal alpha smooth muscle actin antibody (ab7817; Abcam, UK); rabbit polyclonal Involucrin antibody 
(HPA055211; Sigma-Aldrich, USA); mouse monoclonal Cytokeratin 10 antibody (904301; BioLegend, USA); rabbit polyclonal 
Muc5B antibody (ab87376; Abcam, UK); rabbit polyclonal Muc5AC antibody (ab78660; Abcam, UK); goat polyclonal E-Cadherin 
antibody (AF648; R&D Systems, USA). Secondary antibodies used here are Alexa Fluor-488 or Alexa Fluor-594 Donkey anti-goat/
mouse/rabbit IgG antibody (Thermo Fisher, USA). All images were captured by using the Inverted Eclipse Ti-Series (Nikon, Japan) 
microscope with Lumencor SOLA light engine and Andor Technology Clara Interline CCD camera and NIS-Elements Advanced 
Research v.4.13 software (Nikon, Japan) or LSM 780 confocal microscope (Carl Zeiss, Germany) with LSM software. Bright field 
cell culture images were obtained on an Eclipse TS100 microscope (Nikon, Japan) with Digital Sight DSFi1camera (Nikon, Japan) 
and NIS-Elements F3.0 software (Nikon, Japan).
In vitro differentiation
Air-liquid interface (ALI) culture of epithelial clones was performed as described (Kumar et al., 2011; Zuo et al., 2015). Briefly, 
Transwell inserts (Corning, USA) were coated with 20% Matrigel (BD biosciences, USA) and incubated at 37C for 30 min to poly-
merize. 200,000 irradiated 3T3-J2 cells were seeded to each Transwell insert and incubated at 37C, 7.5% CO2 incubator overnight. 
QuadroMACS Starting Kit (LS) (Miltenyi Biotec, Germany) was used to purify epithelial by removal of feeder cells. 200,000-300,000 
cells were seeded into each Transwell insert and cultured in StemECHOTMPU media. At confluency (3-7 days), the apical media on 
the inserts was removed through careful pipetting and the cultures were continued in differentiation media (PneumaCult-ALI Media, 
STEMCELL Technologies, Vancouver) for an additional 14-21 days prior to harvesting. The differentiation media was changed every 
one or two days.
Xenografts in immunodeficient mice
One million epithelial cells were harvested by trypsinization, mixed with 50% Matrigel (Becton Dickinson, Palo Alto) to a volume of 100 
ul and injected subcutaneously in NSG (NODscid IL2ranull) (Shultz et al., 1995) mice (Jackson Laboratories, Bar Harbor) and harvested 
two or four weeks later.
RNA sample preparation
For cell colonies, RNA was isolated using PicoPure RNA Isolation Kit (Life Technologies, USA). For ALI and Xenografts structure, RNA 
was isolated using Trizol RNA Isolation Kit (Life Technologies, USA). RNA quality (RNA integrity number, RIN) was measured by 
analysis Agilent 2100 Bioanalyzer and Agilent RNA 6000 Nano Kit (Agilent Technologies, USA). RNAs having a RIN > 8 were used 
for microarray analysis.
Flow cytometry analysis
Clonogenic cell libraries from patients with or without COPD were trypsinized and harvested as single cell suspension. Feeders 
were removed as mentioned above and approximately 300,000 epithelial cells were fixed and permeabilized by using Fixation/Per-
meabilization Solution Kit (BD biosciences, USA, cat. 554714). After a blocking procedure with Permeabilization solution at 4C for 
30 min, cells were incubated with primary and Alexa Fluor 488 Secondary antibodies (Thermo Fisher, USA) for 1 h at 4C, with five 
washing events between each step. Primary antibodies used in these experiments include: rabbit monoclonal anti-AQP5 antibody 
ab92320 (Abcam, UK), rabbit polyclonal TRPC6 antibody (18236-1-AP; Proteintech, USA), mouse monoclonal anti-human IL-8/
CXCL8 antibody (MAB208; R&D, USA). Samples were collected and analyzed with on a Sony SH800S Cell Sorter (Sony Biotech-
nology, USA).
Transcriptomic sequencing data analysis
All RNA-seq libraries were sequenced on Illumina NovaSeq 6000 with 150 bp pair-end reads. Raw reads were trimmed to remove low 
quality bases (phred score < 20) and sequencing adaptor leftovers using Trim Galore (https://www.bioinformatics.babraham.ac.uk/
projects/trim_galore/) (Martin, 2011). Potential mouse genomic DNA contaminant reads were removed for further analysis using Xen-
ome (Conway et al., 2012). Trimmed RNA-seq reads were mapped to the human genome (UCSC hg19) using Salmon (version 0.9.1) 
with default settings (Patro et al., 2017). Alignment results were then input to DEseq2 (Love et al., 2014) for differential expression 
analysis with default settings and FDR less than 0.05. Batch effects were estimated and corrected using RUVSeq (Risso et al., 
2014). The heatmaps with hierarchical clustering analysis of the global gene expression pattern in different samples were performed 
using pheatmap package (http://cran.rproject.org/web/packages/pheatmap/index.html) (Li et al., 2018) in R (version 3.5.1). The 
pathway enrichment analysis was performed using Enrichr (Chen et al., 2013) and Ingenuity Pathway Analysis (IPA) tools (Krä mer 
et al., 2014).
Sequence alignment of single cell RNA sequencing
The single cell mRNA sequencing (scRNA-seq) libraries were established using the 10X Genomics Chromium system (Single Cell 30
Reagent Kit v2). The scRNA-seq libraries were sequenced on the Illumina HiSeq X Ten with 10K cells for three COPD cases and fetal
lung case. For three normal cases, the scRNA-seq libraries were sequenced on the Illumina NextSeq 500 with 2K cells. Demultiplex-
ing, alignment and UMI-collapsing were performed using the Cellranger toolkit (version 2.1.0, 10X Genomics) (Ferguson and Chen,
2020). The raw paired-end reads were trimmed to 26 bps for Read1 and 98 bps for Read2. The trimmed reads were mapped to both
the human genome (hg19) and the mouse genome (mm10). The reads uniquely mapped to the human genome were used for
downstream analysis.
Single cell RNA sequencing
The scRNA-seq data analyses were performed using the Seurat package (version 2.3.4) (Satija et al., 2015). We kept the genes with
expression in at least three cells, and excluded cells expressing less than 200 genes. We also excluded the cells with high mitochon-
drial percentage or with an outlier level of UMI content. The normalization was performed using the global-scaling normalization
method, which normalizes the gene expression measurements for each cell by the total expression, and then multiplies by
10,000, and finally log-transforms the result. The variable genes were identified using a function to calculate average expression
and dispersion for each gene, divides these genes into bins, and then calculates a z-score for dispersion within each bin (‘‘x.low.cut-
off = 0.0125,’’ ‘‘x.high.cutoff = 3,’’ and ‘‘y.cutoff = 0.5’’). We scaled the data to regress out the variation of mitochondrial gene
expression.
We performed PCA based on the scaled data to identify significant principal components (PCs). We selected the PCswith p values
less than 0.01 as input to perform clustering analysis and visualization by t-SNE. We detected the marker genes in each cell subpop-
ulation using two methods of Wilcoxon rank sum test and DESeq2. For Wilcoxon rank sum test, we used the default parameter. For
DEseq2, we kept the marker genes with average log-fold change above 0.1 and adjust p value fewer than 0.05.
Contaminating 3T3-J2 fibroblast cells were identified by murine reads. In addition, the cells in S stage of cell cycle were identified
based on the marker gene of SLBP (Nestorowa et al., 2016). The cells in G2 or M stage of cell cycle were identified based on the
marker genes of UBE2C, AURKA, CENPA, CDC20, HMGB2, CKS2, and CKS1B. The cells in G0 stage of cell cycle were identified
based on the marker genes of G0S2. In addition, the ambiguous cells with few marker genes were also removed, which could
possibly correspond to sequencing low quality cells. Finally, we integrated the clean data of six cases to perform clustering analysis
and visualization by t-SNE.
Expression microarray and bioinformatics
Total RNAs obtained from immature colonies and ALI-differentiated epithelia were used for microarray preparation with WT Pico
RNA Amplification System V2 for amplification of DNA and Encore Biotin Module for fragmentation and biotin labeling (NuGEN
Technologies, USA). All samples were prepared according to manufacturer’s instructions and hybridized onto GeneChip Human
Exon 1.0 ST array (Affymetrix, USA). GeneChip operating software was used to process Cel files and calculate probe intensity
values. To validate sample quality, quality checks were conducted using Affymetrix Expression Console software. The intensity
values were log2-transformed and imported into the Partek Genomics Suite 6.6 (Partek Incorporated, USA) (Wodehouse et al.,
2019). Exons were summarized to genes and a 1-way ANOVA was performed to identify differentially expressed genes. Unsuper-
vised clustering and heatmap generation were performed with sorted datasets by Euclidean distance based on average linkage by
Partek Genomics Suite 6.6.
Whole genome exome sequencing data analysis
For exomecaptureandhigh-throughput sequencing, genomicDNAwas isolated fromsingle cell-derivedpedigreesand1000ngofDNA
per samplewere sheared, end-repaired, A-tailed and adaptor-ligated. Exomecapturewasconducted using the Agilent SureSelect Hu-
man All Exon V6Kit following themanufacturer’s standard protocols. The librarieswere sequenced on an IlluminaHiSeq X ten platform
(150 bp paired-endmodel). The raw sequencing data were quality controlled by Trimmomatic (Bolger et al., 2014) version 0.36 to trim
low-quality bases, filtered by Xenome (Conway et al., 2012) version 1.0.1 to remove mouse sequences, aligned to reference genome
(hg19) via BWA-mem (Li and Durbin, 2010) version 0.7.15, realigned throughGATK (McKenna et al., 2010) version 3.8.0 in regions near
indels (Mills_and_1000G_gold_standard indels), and recalibrated with default settings following the best practices pipeline of GATK
(Van der Auwera et al., 2013). Somatic SNVs and Indels were called by Manta (Chen et al., 2016) version 1.3.2 and Strelka (Kim
et al., 2018) version 2.9.2 and annotatedwith ANNOVAR (Yang andWang, 2015).We require that somaticmutations situated at the tar-
getedcapturing regions,pass theStrelkadefault filters, andhaveonly twogenotypespresent, aminimumof5%mutant reads fraction,a
minimum 5mutant reads coverage, andminimum 15 total reads coverage. The correspondingmatched normal sample should be ho-
mozygous wild type at the mutation sites. Somatic mutations were further filtered to remove possible germline mutations based on a
panel of 27 normal samples. Somatic mutations with allele frequencies larger than 0.01 in 1000 Genomes database (Sudmant et al.,
2015) or gnomAD database v2 (Karczewski et al., 2019) were discarded as well. The somatic allelic copy number variants were called
by the best practices pipeline of GATK version 4.0.4 (DePristo et al., 2011; Van der Auwera et al., 2013). The modeled copy number
segments with less than 7.5 Kbp in length or less than 15 common variants were filtered out. We used default settings in all software.
The oncogenes and tumor suppressors were fetched from the OncoKB database (Chakravarty et al., 2017).
QUANTIFICATION AND STATISTICAL ANALYSIS
Unpaired two-tailed Student’s t test was used to determine the statistical significance between two groups. Statistical analyses were
performed using R (version 3.5.1). The ‘‘n’’ numbers for each experiment are provided in the text and figures. p < 0.05was considered
statistically significant. Asterisks denote corresponding statistical significance *p < 0.05; **p < 0.01; ***p < 0.001 and ****p < 0.0001.
DATA AND CODE AVAILABILITY
The microarray, single-cell RNA-seq, RNA-seq, and exome sequencing datasets generated during this study are available at GEO:
GSE118950, SRA: PRJNA514053, and SRA: PRJNA492749. A list of software used in this study can be found in the Key Re-
sources Table.
(legend on next page)
Supplemental Figures
Figure S1. In Vitro and In Vivo Differentiation of Cluster 1–4 Clones, Related to Figure 2
A. H&E staining of histological sections of air-liquid interface (ALI)-differentiated cluster 1-4 clones. Scale bar, 100 mm.
B. Left, Immunohistochemistry of p63 antibody staining (brown) of the distal airway of normal human lung. Scale bar, 500 mm. Right from top, Magnification of
indicated terminal bronchiole epithelium region of p63 immunohistochemistry; immunofluorescence micrograph of terminal bronchiolar epithelium stained with
DAPI, anti-p63, anti-SCGB1A1, and anti-SFTPB, and immunofluorescence micrograph of terminal bronchiolar epithelium showing anti-p63 and anti-AQP4
staining. Alveo, alveolar epithelia. Scale bar, 100 mm.
C-F. Immunofluorescence micrographs of xenograft sections derived from transplants of clones of clusters 1-4 probed with the indicated antibodies. Scale
bar, 100 mm.
G. Venn diagrams showing overlap between nonsynonymous SNV events detected from whole genome exome sequencing of clones of clusters 1-4 from COPD
(SNP-13) lung and 202 oncogenes and 231 tumor suppressor genes (detailed in Table S5).
(legend on next page)
Figure S2. Distribution of Metaplasia in Stage 4 COPD Lung, Related to Figure 3
A. Immunohistochemistry micrograph of section of distal lung of normal donor showing distribution of p63 staining (brown) in bronchioles and terminal bron-
chioles. Scale bar, 1,000 mm. Boxed region indicates region presented as inset right top) and corresponding region of serial section examined by p63 and AQP5
immunofluorescence (lower right). Scale bar of insets, 100 mm.
B. Immunohistochemistry micrograph of Stage 4 COPD distal lung stained with p63 antibodies (brown). (*) denote regions of submucosal inflammation. Scale bar,
1,000 mm. Boxed regions corresponding to iSCM, GCM, and SCM are shown at higher magnification below along with immunofluorescence micrographs of similar
regions from serial sections stained with antibodies to p63/CXLC8 (iSCM), p63/TRPC6 (GCM), and p63/TRPC6 (SCM). Inset region scale bars, 100 mm.
Figure S3. Clone Variant Analysis by scRNA-Seq, Related to Figure 3
A. Differential gene expression determined by scRNA-seq of three COPD and three control clone libraries and the corresponding differential gene expression
determined by RNA-seq of discrete clones of clusters 1-4 of SPN-13 (detailed in Tables S6, S7).
B. tSNE profiles of single cell RNA-seq data derived from clone libraries from the individual COPD and control cases.
C. Mapping of cluster-specific gene expression markers onto an integrated tSNE profile assembled from three Control and three COPD cases.
(legend on next page)
Figure S4. Leukocyte TEM in Xenografts, Related to Figure 4
A. Box-Whisker plot representation of cluster 2-4 FACS proportions in each of 19 COPD and 11 control libraries (p < 2.2e-16, Student’s t test)
B.,C. Histological sections through nodules formed four weeks after transplantation of clonogenic cell pools of six representative non-COPD cases (upper) and
COPD cases (lower) to immunodeficient mice. Scale bar, 200 mm.
D. Box-Whisker plot representation of severe inflammation fraction in each of 19 COPD and 11 control library xenografts (p = 1.2e-09, Student’s t test).
(legend on next page)
Figure S5. Inflammatory Gene Expression by Clones of Clusters 1 to 4, Related to Figure 5
A. Top 10 pathways of differentially expressed genes (FDR < 0.05) of patient-matched clones representative of clusters 1-4 using Ingenuity Pathway Analysis
(IPA) software.
B. Immunofluorescence of Vcam1 (red) in human lung endothelial cells following exposure to media conditioned by clones of clusters 1-4 compared to IL-13
challenge. Scale bar, 100 mm.
C. Expression heatmaps (FDR < 0.05) depicting pairwise gene expression analysis of clusters 1-4 focused on chemokine, interleukin, and interferon genes.
Figure S6. Fibrosis in Xenografts, Related to Figure 6
A., B. Immunofluorescence micrographs of sections of nodules formed four weeks after transplantation of clone libraries from six representative control cases
(upper) and COPD cases (lower). Green, E-cad, E-cadherin; red, SMA, anti-alpha smooth muscle actin. Scale bar, 200 mm.
C. Immunofluorescencemicrographs of E-cadherin (Ecad) and alpha smoothmuscle actin (SMA) expression in xenografts of clones of cluster 3 (left) and cluster 4
(right) from in vitro passage 5 and passage 25. Scale bar, 100 mm.
(legend on next page)
Figure S7. Variant Clones in Normal Adult and Fetal Lung, Related to Figure 7
A. Histology and marker analysis of xenografts of cloned representatives of clusters 1-4 from adult Control lung (SPN-14).
B. Left, Principal component analysis of RNA-seq profiles of clusters 1-4 clones from control lung (SPN-14) and those of clusters 1-4 of two COPD cases (SPN-7
and SPN-13). Right, Expression heatmap comparing RNA-seq profiles of clusters 1-4 clones of control lung (SPN-14) with those of clones of COPD cases SPN-7
and SPN-13 (detailed in Table S8).
C. Histology of pseudoglandular epithelia of 13-wk fetal lung and marker immunofluorescence including antibodies to p63, AQP5, AQP4, a-TUB, and SFTPB.
D. Left, Distribution of cluster-specific expression markers on scRNA-seq tSNE profile of clone library from 13-wk fetal lung. Right, Pie chart showing distribution
of variants in 13-wk fetal library.
E. Dot plots of expression for cluster-specific marker genes in the integrated tSNE profiles of lung clones from three adult Controls, three COPD cases, and the
13-wk fetal lung. The size of the dot corresponds to the percentage of cells expressing the feature in each cluster. The color represents the average expres-
sion level.
